Latest Breaking News On - Oral drug - Page 1 : comparemela.com

AstraZeneca moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive licence to develop an experimental oral drug in the field. The Anglo-Swedish drugmaker said it had struck the deal for ECC5004, a once-daily oral drug that is part of a class of highly promising weight-loss medicines known as GLP-1 receptor agonists currently dominated by Novo Nordisk and Eli Lilly, which have injectable products. Astra, alongside reporting quarterly results, said Eccogene would receive $185 million up front, plus up to $1.825 billion depending on certain clinical, regulatory, and commercial achievements.

United kingdomCity ofYadarisa shabongEli lilly zepboundLudwig burgerNovo wegovyNovo nordisk wegovyEli lillyMark potterJason neelyNovo nordiskEli lillyOral drugAnti obesityInjectable products